Free Trial

CG Oncology (CGON) Stock Price, News & Analysis

CG Oncology logo
$25.96 -0.29 (-1.10%)
Closing price 04:00 PM Eastern
Extended Trading
$25.96 +0.00 (+0.02%)
As of 05:05 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About CG Oncology Stock (NASDAQ:CGON)

Key Stats

Today's Range
$25.83
$26.95
50-Day Range
$21.70
$29.05
52-Week Range
$14.80
$40.47
Volume
1.03 million shs
Average Volume
849,125 shs
Market Capitalization
$1.98 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$58.67
Consensus Rating
Buy

Company Overview

CG Oncology Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
47th Percentile Overall Score

CGON MarketRank™: 

CG Oncology scored higher than 47% of companies evaluated by MarketBeat, and ranked 577th out of 922 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    CG Oncology has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 9 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    CG Oncology has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about CG Oncology's stock forecast and price target.
  • Earnings Growth

    Earnings for CG Oncology are expected to decrease in the coming year, from ($1.31) to ($1.77) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of CG Oncology is -17.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of CG Oncology is -17.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    CG Oncology has a P/B Ratio of 2.70. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about CG Oncology's valuation and earnings.
  • Percentage of Shares Shorted

    24.69% of the float of CG Oncology has been sold short.
  • Short Interest Ratio / Days to Cover

    CG Oncology has a short interest ratio ("days to cover") of 8.1.
  • Change versus previous month

    Short interest in CG Oncology has recently decreased by 10.21%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    CG Oncology does not currently pay a dividend.

  • Dividend Growth

    CG Oncology does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    24.69% of the float of CG Oncology has been sold short.
  • Short Interest Ratio / Days to Cover

    CG Oncology has a short interest ratio ("days to cover") of 8.1.
  • Change versus previous month

    Short interest in CG Oncology has recently decreased by 10.21%, indicating that investor sentiment is improving significantly.
  • MarketBeat Follows

    Only 1 people have added CG Oncology to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, CG Oncology insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $30,760.00 in company stock.

  • Percentage Held by Institutions

    Only 26.56% of the stock of CG Oncology is held by institutions.

  • Read more about CG Oncology's insider trading history.
Receive CGON Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CG Oncology and its competitors with MarketBeat's FREE daily newsletter.

CGON Stock News Headlines

CG Oncology (NASDAQ:CGON) Raised to "Hold" at Wall Street Zen
CGON - CG Oncology Inc Trailing Returns - Morningstar
Thirty-Year “Wonder Material” Finally Ready for Factory Floors
A Nobel-recognized material once trapped in research labs is finally ready for the real world. After a 90% cost breakthrough, this wonder-material is being tested by aerospace giants, battery developers, and chip makers alike. Now, a new briefing reveals the companies best positioned to profit from its mass adoption.
See More Headlines

CGON Stock Analysis - Frequently Asked Questions

CG Oncology's stock was trading at $28.68 at the beginning of 2025. Since then, CGON shares have decreased by 9.5% and is now trading at $25.96.

CG Oncology, Inc. (NASDAQ:CGON) issued its quarterly earnings results on Tuesday, May, 13th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.36) by $0.09. The firm earned $0.05 million during the quarter, compared to analysts' expectations of $0.53 million. CG Oncology had a negative trailing twelve-month return on equity of 16.71% and a negative net margin of 15,945.17%.

CG Oncology (CGON) raised $380 million in an IPO on Thursday, January 25th 2024. The company issued 20,000,000 shares at $19.00 per share.

Top institutional shareholders of CG Oncology include Wesbanco Bank Inc. (0.04%). Insiders that own company stock include Hong Fang Song, Decheng Capital Global Life Sc, Corleen M Roche, Vijay Kasturi and Leonard E Post.
View institutional ownership trends
.

Shares of CGON stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that CG Oncology investors own include Invesco QQQ (QQQ), SPDR Dow Jones Industrial Average ETF Trust (DIA), SPDR S&P 500 ETF Trust (SPY), Meta Platforms (META), Advanced Micro Devices (AMD), NVIDIA (NVDA) and Tesla (TSLA).

Company Calendar

Last Earnings
5/13/2025
Today
7/08/2025
Next Earnings (Estimated)
8/14/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:CGON
Previous Symbol
NASDAQ:CGON
Fax
N/A
Employees
61
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$58.67
High Stock Price Target
$75.00
Low Stock Price Target
$23.00
Potential Upside/Downside
+124.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
11 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$88.04 million
Net Margins
-15,945.17%
Pretax Margin
-15,945.17%

Debt

Sales & Book Value

Annual Sales
$1.14 million
Price / Cash Flow
N/A
Book Value
$9.63 per share
Price / Book
2.71

Miscellaneous

Free Float
N/A
Market Cap
$1.99 billion
Optionable
Optionable
Beta
0.86
7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

This page (NASDAQ:CGON) was last updated on 7/8/2025 by MarketBeat.com Staff
From Our Partners